Pharmacy- Page 2

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has

Bayer launches first Global Creative Council

The FINANCIAL — Bayer launches its first Global Creative Council. This global initiative brings together senior leaders from a variety of companies representing strategic agencies as well as industry brands. The Council aims to harness progressive and collective creativity of industry marketing
October 29, 2020
2 mins read

Lilly announced third-quarter earnings

The FINANCIAL — Lilly reported Q3 financial results:  – Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent.
October 27, 2020
1 min read

Gilead completed acquisition of Immunomedics

The FINANCIAL — Gilead Sciences, Inc. (Nasdaq: GILD) announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate. “We are very pleased to reach today’s milestone and to welcome the talented
October 26, 2020
1 min read

Bayer acquires AskBio for $4 bln

The FINANCIAL — Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s development portfolio includes investigational pre-clinical and clinical stage candidates
October 26, 2020
3 mins read

Lilly to acquire Disarm Therapeutics

THe FINANCIAL — Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and is advancing
October 19, 2020
1 min read

Get updates

Join

We hate spams like you do

Latest comments

Go toTop